Lentivirus |
Sustain gene expression |
Insertional mutagenesis |
Replacement gene therapy |
|
Acceptable coding capacity |
Prone to recombination |
Inherited genetic disorder |
|
No mutagenicity |
Potential for silencing |
|
|
High transduction efficiency in vitro and acceptable transduction efficiency in vivo
|
Expensive |
|
Oncoretrovirus |
Sustain gene expression |
Insertional mutagenesis |
Replacement gene therapy |
|
Acceptable coding capacity |
Prone to recombination |
Inherited genetic disorder |
|
No mutagenicity |
Potential for silencing |
Trans-splicing RNA repair |
|
High transduction efficiency in vitro
|
Cannot transduce non-dividing cells |
|
|
|
Expensive |
|
Adenovirus |
Does not integrate into host genome |
Transient gene expression |
Antitumor therapy |
|
High transduction efficiency in vitro
|
Immunogenic |
Chronic non-healing ulcer |
|
High coding capacity |
Expensive |
|
|
Stable |
|
|
Adeno-associated virus |
Sustain gene expression |
Insertional mutagenesis |
Homology directed mutation repair |
|
High transduction efficiency in vivo and ex vivo
|
Low coding capacity |
|
|
Low immunogenicity |
Immunogenic after repeated administration |
Inherited genetic disorder |
|
Stable |
Expensive |
Systemic disease |
Nonviral (plasmid DNA) |
Does not integrate into host genome |
Transient gene expression |
Antitumor therapy |
|
High coding capacity |
Risk of “Off target” genome editing |
Chronic non-healing ulcer |
|
In vivo administration |
Nonselective |
Vaccination |
|
No immunogenicity |
Low efficiency |
Inherited genetic disorder |
|
Inexpensive |
|
Homology directed mutation repair and genome editing |
|
Stable |
|
|